Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu
Trial record 26 of 1197 for:    MYCOPHENOLIC ACID

Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablets of Dr.Reddy's Laboratories Limited Under Non-Fasting Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01283867
Recruitment Status : Completed
First Posted : January 26, 2011
Last Update Posted : January 26, 2011
Information provided by:
Dr. Reddy's Laboratories Limited

Brief Summary:
To compare the bioavailability and characterise the pharmacokinetic profile of the sponsor's test formulation with respect to the reference formulation Cellcept® 500 mg tablets, in healthy, adult, human male subjects under non-fasting conditions and to assess the bioequivalence.

Condition or disease Intervention/treatment Phase
FED Drug: Mycophenolate Mofetil Phase 1

Detailed Description:
This was an open-label, balanced, randomized, two-treatment, two-period, two-sequence,single dose, crossover bioequivalence study in healthy, adult, human, male subjects under non-fasting conditions.92 healthy male adults were enrolled.A washout period of 07 days was maintained between the successive dosing days.One tablet containing mycophenolate mofetil 500 mg was administered orally with 240 mL water in sitting posture, after 30 minutes of serving of the high fat and high calorie breakfast in each period. This activity was followed by a mouth check to assess compliance to dosing. The subjects were not allowed to lie down for the first three hours after dosing.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 92 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablet of Dr. Reddy's Laboratories Limited Comparing With That of Cellcept 500 mg Tablet of Roche Laboratories in Healthy, Adult,Human, Male Subjects Under Non-fasting Conditions.
Study Start Date : November 2007
Actual Primary Completion Date : December 2007
Actual Study Completion Date : December 2007

Arm Intervention/treatment
Experimental: Mycophenolate Mofetil
Mycophenolate Mofetil 500 mg tablets of Dr. Reddy's Laboratories Limited
Drug: Mycophenolate Mofetil
Mycophenolate Mofetil 500 mg tablets
Other Name: Cellcept

Active Comparator: Cellcept
Cellcept 500 mg tablets of Roche Laboratories Inc.
Drug: Mycophenolate Mofetil
Mycophenolate Mofetil 500 mg tablets
Other Name: Cellcept

Primary Outcome Measures :
  1. Bioequivalence on Cmax and AUC parameters [ Time Frame: 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Healthy males between 18-45 years of age (both inclusive) living in and around Mumbai city of western part of India.
  2. Having a weight more than or equal to 50 Kg and having a Body Mass Index (BMI)between 18.5-24.9 (both inclusive), calculated as weight in kg / height in m2.
  3. Having no significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination, laboratory evaluations, 12-lead ECG and chest X-ray (postero-anterior view) recordings.
  4. Able to comply with the study procedures, in the opinion of the Principal Investigator.
  5. Able to give written consent for participation in the trial.

Exclusion Criteria:

  1. Known hypersensitivity or idiosyncratic reaction to Mycophenolate Mofetil or any drug.
  2. Any disease or condition which might compromise the haemopoietic, renal, hepatic,endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological,gastrointestinal or any other body system.
  3. Ingestion of a medicine at any time with in 14 days before dosing in Period-I. In any such case subject selection will be at the discretion of the Principal Investigator /Medical Expert.
  4. Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or NSAID induced urticaria.
  5. A recent history of alcoholism (<2 years) or of moderate (180 mL / day) alcohol use, or consumption of alcohol within 48 hours of receiving study medicine.
  6. Smokers, who had a habit of smoking 10 or more than 10 cigarettes / day or could, not abstain from smoking during the study.
  7. The presence of clinically significant abnormal laboratory values during screening.
  8. Use of any recreational drugs or history of drug addiction or testing positive in pre-study urine drug scan.
  9. History of psychiatric disorders.
  10. A history of difficulty with donating blood.
  11. Donation of blood (1 unit or 350 mL) within 90 days prior to receiving the first dose of the study medicine or during the study.

    Note: In case the blood loss was ≤ 200 mL, the subject was enrolled 60 days after blood donation.

  12. A positive hepatitis screen including hepatitis B surface antigen and anti-HCV antibodies.
  13. A positive test result for HIV antibody and / or syphilis.
  14. The receipt of an investigational product or participation in a drug research study within a period of 90 days prior to the first dose of study medication. Elimination half-life of the study drug was taken into consideration for inclusion of the subject in the study.

    Note: If the subject had participated in a study in which blood loss was ≤ 200 mL, the subject was dosed 60 days after the collection of last sample in the previous study.

  15. An unusual diet, for whatever reason (e.g. low-sodium), for four weeks prior to receiving the study medicine and throughout the subject's participation in the study. In any such case selection of the subject will be at the discretion of the Principal Investigator/Medical Expert.
  16. Uric acid parameters at the time of screening are not within clinically acceptable range.
  17. History of gout and renal calculi.
  18. Sitting blood pressure less than 100/60 mm Hg at the time of screening.
  19. Haemoglobin less than 13 gm/dL at the time of screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01283867

Layout table for location information
Lambda Therapeutic Research Ltd
Bodakdev, Ahmedabad, India, 3 80 054
Sponsors and Collaborators
Dr. Reddy's Laboratories Limited
Layout table for investigator information
Principal Investigator: T Gitanjali, MD Lambda Therapeutic Research Ltd.

Layout table for additonal information
Responsible Party: Director-Research & Development, Dr. Reddy's Laboratories Limited Identifier: NCT01283867    
Other Study ID Numbers: 295-07
First Posted: January 26, 2011    Key Record Dates
Last Update Posted: January 26, 2011
Last Verified: January 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Mycophenolic Acid
Antibiotics, Antineoplastic
Antineoplastic Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action